Oxford scientists expect trials data by Christmas

Early results indicate AstraZeneca/Oxford vaccine is promising

Early results indicate AstraZeneca/Oxford vaccine is promising

The findings were based on a so-called phase II trial of 560 people, including 240 over the age of 70.

The vaccine produced fewer side-effects (like temporary fatigue) in the older age group, and blood samples proved it prompted a powerful immune response.

The ongoing phase 3 trial is assessing the vaccine for its effectiveness, or in other words, whether it can protect people from COVID-19. "The next step will be to see if this translates into protection from the disease itself", he added.

Many other airports and airlines are also learnt to be preparing for vaccine transportation - possibly the largest ever air cargo opportunity so far; comments from them were awaited.

The study's lead author, Andrew Pollard from the University of Oxford also told The Guardian, "Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections".

"As a result, it is crucial that COVID-19 vaccines are tested in this group who are also a priority group for immunization", he said in a news release from the journal The Lancet. Instead, it looked at safety indicators and the body's immune response. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus. And it turns out that older adults are less likely to have local reactions where they got the injection and symptoms on the day of vaccination compared to younger people.

Vials of the Oxford coronavirus vaccine
Vials of the Oxford coronavirus vaccine

According to the research, the adverse reactions were mild. Moderna's vaccine is expected to be stable at normal fridge temperatures for 30 days but for storage of up to six months, it needs to be kept at minus 20 deg C. But since that work was done the trial has been expanded to include tens of thousands of individuals - a Phase 3 trial.

However, experts have warned against the vaccine due to a lack of standard control from any clinical trial group.

United Kingdom authorities have placed orders for 100 million doses of the vaccine - enough to vaccinate most of the population - should it receive regulatory approval.

The U.S. Food and Drug Administration's outside advisers will meet on December 10 to discuss whether to authorize the COVID-19 vaccine developed by Pfizer Inc PFE.N and German partner BioNTech 22UAy.DE for emergency use, the agency said on Friday.

Separately, Pfizer's chief executive Albert Bourla said on Tuesday that the firm plans to submit its vaccine data to the US Food and Drug Administration for emergency-use authorisation.

Facebook Details Amount Of Hate Speech On Its Platform
Facebook admitted that defining hate speech isn't simple, as there are many differing opinions on what constitutes hate speech. Without informing the public, Facebook undertook a massive live experiment in heavily automated content moderation.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.